CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Eleven Biotherapeutics, a biopharmaceutical company designing and developing novel and differentiated protein-based biotherapeutics for ocular diseases, announced today that Abbie Celniker, PhD, Chief Executive Officer of Eleven Biotherapeutics is scheduled to provide a corporate update at the Stifel Nicolaus 2013 Healthcare Conference in Boston on Thursday, September 12, 2013 at 2:05 p.m. Eastern Time.
About Eleven Biotherapeutics
Eleven Biotherapeutics designs and develops protein therapeutics that are able to optimally target key points in disease pathways that drive both ocular surface and back of the eye diseases. The company’s proprietary technology platform creates first-of-a-kind protein therapeutics to treat ocular diseases in new and more effective ways. Current pipeline opportunities include ocular surface diseases such as dry eye disease and severe allergic conjunctivitis as well as other ocular diseases such as diabetic macular edema and uveitis. EBI-005, Eleven’s lead product candidate, is a novel, clinically-validated, interleukin-1 (IL-1) receptor antagonist in clinical development as one of the first topically administered proteins for the treatment of inflammatory diseases at the surface of the eye including dry eye disease. Beyond its internal drug development programs, the company is working with collaborators to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. The Cambridge, Mass.-based company was founded in 2010 by life science investors Flagship Ventures and Third Rock Ventures and world-renowned scientific experts. For more information, please visit www.elevenbio.com.